Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

“At just 40% of the administered dose reported for Ac-DOTATATE, Ac-EBTATE produces enhanced anti-tumor efficacy in small cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as ...